July 2, 2019
FSD Pharma Closes Deal to Acquire Prismic Pharmaceuticals
FSD acquires platform company to advance R&D of targeted application of micro-Palmitoylethanolamide impacting the human endocannabinoid system
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
July 2, 2019
ZULRESSO Launched by Sage Therapeutics, 11th FDA-approved drug to use Ligand’s Captisol technology
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy.
July 2, 2019
Pfizer Completes Acquisition of Therachon
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG.
July 1, 2019
Smithers Avanza Names Frank M. Rotella Director of Operations at New Jersey Laboratory
New Jersey Expansion Broadens Service Portfolio Currently Offered in Maryland EWING, N.J.–(BUSINESS WIRE)–#NewJersey—Smithers Avanza, a contract research organization (CRO) supporting…
July 1, 2019
Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history of peanut allergy
June 30, 2019
Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension
Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the efficacy and safety of intravenous (IV) sildenafil when added to inhaled nitric oxide (iNO) for the treatment of newborns with Persistent Pulmonary Hypertension (PPHN) did not meet its primary efficacy endpoint.
June 28, 2019
Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)
Pfizer will present initial Phase 1b clinical data on PF-06939926, an investigational gene therapy to potentially treat Duchenne muscular dystrophy (DMD) at the 25th Annual Parent Project Muscular Dystrophy (PPMD) Connect Conference in Orlando, FL. These are preliminary data drawn from a small number of participants in an ongoing study.
June 28, 2019
Glenmark Pharmaceuticals granted Ezetimibe, Simvastatin tablets in USA
Indian Glenmark Pharmaceuticals has been granted final approval by the U.S. FDA for Ezetimibe and Simvastatin Tablets, for several doses.
June 28, 2019
Pfizer gets U.S. FDA approval for its oncology biosimilar, ZIRABEV
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved ZIRABEV™ (bevacizumab-bvzr), a…
June 27, 2019
FDA to review Sanofi’s MenQuadfi, for meningococcal meningitis
Sanofi’s MenQuadfi Meningococcal Polysaccharide Tetanus Toxoid Conjugate Vaccine candidate to help prevent meningococcal meningitis will be reviewed for BLA by the FDA, expecting to reach the decision on April 25, 2020.